Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions

ER+ and AR+ Breast Cancer

Interventions

DRUG

GTx-024

To determine whether either or both doses result in an acceptable clinical benefit rate.

Trial Locations (4)

Holy Cross Hospital, Fort Lauderdale

The West Clinic, PC, Memphis

St. Vincent Frontier Cancer Center, Billings

Dana Farber Cancer Institute, Boston